215
Participants
Start Date
May 23, 2014
Primary Completion Date
May 8, 2016
Study Completion Date
September 29, 2017
Enzalutamide
Participants received 160 mg of enzalutamide (soft capsules) orally once daily.
Site BE32001, Brussels
Site BE32007, Hasselt
Site BE32002, Liège
Site BE32003, Kortrijk
Site ES34009, Badalona
Site BE32004, Ghent
Site DE49014, Berlin
Site DE49003, Berlin
Site FR33003, Marseille
Site FR33009, Caen
Site ES34004, Santiago de Compostela
Site DE49001, Hamburg
Site DE49008, Hamburg
Site ES34001, Madrid
Site ES34003, Madrid
Site ES34002, Madrid
Site ES34010, Madrid
Site FR33002, Nîmes
Site DE49007, Hanover
Site FR33007, Rennes
Site DE49004, Göttingen
Site DE49016, Düsseldorf
Site FR33008, Nantes Saint Herblain Cedex
Site DE49017, Duisburg
Site DE49012, Münster
Site FR33015, Angers
Site DE49015, Bergisch Gladbach
Site DE49009, Bonn
Site FR33013, Lyon
Site DE49002, Heidelberg
Site FR33014, Le Mans
Site DE49006, Tübingen
Site DE49005, Nürtingen
Site FR33011, Paris
Site FR33001, Paris
Site FR33005, Suresnes
Site FR33010, Créteil
Site FR33012, Villejiuf
Site DE49010, Dresden
Site ES34011, Barcelona
Site ES34006, Barcelona
Site ES34008, Barcelona
Site GB44001, Sutton
Site GB44004, Birmingham
Site GB44009, Brighton
Site GB44002, Glasgow
Site GB44007, London
Site GB44003, Northwood, Middlesex
Site GB44010, Plymouth
Site GB44006, Withington
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
INDUSTRY
Astellas Pharma Europe B.V.
INDUSTRY